Clinical Trials on GastroEsophageal Cancer

Total 52083 results

Massachusetts General Hospital
National Cancer Institute (NCI)

Active, not recruiting

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

GastroEsophageal Cancer

United States
Jesper Frank Christensen, PhD
Lundbeck Foundation; Region Capital Denmark; Beckett Foundation

Active, not recruiting

PREoperativ Study of Exercise Training (PRESET-RCT)

GastroEsophageal Cancer

Denmark
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients (STRONG-GEC)

GastroEsophageal Cancer

United States
Rigshospitalet, Denmark
Danish Cancer Society

Completed

Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer

Gastroesophageal-junction Cancer

Denmark
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
M.D. Anderson Cancer Center

Recruiting

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Gastrostomy | GastroEsophageal Cancer | Gastric

United States, Japan, Korea, Democratic People's Republic of
Amgen

Completed

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Cancer

Japan
Centre Leon Berard

Recruiting

GastrOesophageal Tumor, Immune Microenvionnment (GOTIM) (GOTIM)

GastroEsophageal Cancer

France
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
Charite University, Berlin, Germany

Not yet recruiting

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer

Gastric and Gastroesophageal Junction Cancer

Germany
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
Memorial Sloan Kettering Cancer Center

Terminated

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Gastric Cancer | Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Junction Cancer | Gastric Tumor | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer | Esophageal Tumor | Esophagogastric Tumors | Gastroesophageal Junction Tumor

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
Tang-Du Hospital

Enrolling by invitation

A Clinical Study of Laparoscopic Proximal Gastrectomy Based on PTST(Parachute-tunnel- Style Technique) Esophagogastric Anastomose.

Gastroesophageal-junction Cancer | Proximal Gastrectomy | Gastroesophagostomy

China
GeneScience Pharmaceuticals Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaborators

Unknown

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Advanced Gastric or Gastroesophageal Junction Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION)

Gastroesophageal Cancer | Immune Checkpoint Inhibition

United States
Cantonal Hospital of St. Gallen

Completed

Diagnostic Value of C-reactive Protein for Detection of Postoperative Inflammatory Complications After Gastroesophageal Cancer Surgery

Given Indication for Gastroesophageal Cancer Surgery

Switzerland
Roswell Park Cancer Institute
Pfizer

Recruiting

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Advanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Inova Health Care Services
George Mason University

Recruiting

A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer (BAISIC)

GastroEsophageal Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Not yet recruiting

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditions

United States
Hanmi Pharmaceutical Company Limited

Completed

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

Non-erosive Gastroesphageal Reflux Disease

Korea, Republic of
Yonsei University

Completed

Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease

Non-erosive Gatroesophageal Reflux Disease

Korea, Republic of
Apexigen America, Inc.

Completed

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Esophageal Cancer | GastroEsophageal Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
University of Wisconsin, Madison

Active, not recruiting

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Resectable Esophageal Cancer | GastroEsophageal Cancer

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Withdrawn

STRENGTH Expansion

Esophageal Cancer | Gastroesophageal Junction Cancer

United States
Novartis

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroespohageal Reflux Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Peritoneal Carcinomatosis | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
Rikshospitalet University Hospital

Completed

PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy

Gastroesophageal Junction Cancer

Denmark
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States
Kantonsspital Liestal
University of Bern

Completed

Esophageal Stump Washout

Esophageal Cancer | Gastrooesophageal Cancer

Switzerland
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Esophageal Cancer | Gastroesophageal Junction Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Cancer | Advanced Cancer | Gastroesophageal-junction Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric... and other conditions

United States
The Second Hospital of Shandong University

Recruiting

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Esophageal Cancer | Immunotherapy | Gastroesophageal Cancer | Adjuvant

China
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Ukrainian Society of Clinical Oncology

Recruiting

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction Adenocarcinoma

Ukraine
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Nataliya Uboha
Eli Lilly and Company

Terminated

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Adenocarcinoma | Gastroesophageal Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Gastroesophageal Cancer
ImmVirx Pty Ltd

Recruiting

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Colorectal Cancer | Ovarian Cancer | Gastroesophageal Cancer

Australia
Société Française d'Endoscopie Digestive

Not yet recruiting

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) (ANTIMIG)

GastroEsophageal Cancer | Stent Migration

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States

Clinical Trials on GastroEsophageal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations